SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
74:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Continued  research  in  this area  has fo-:@0.084242:0.096166:0.475169:0.096166:0.475169:0.080410:0.084242:0.080410:0.015644:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.012508:0.013181:0.005330:0.005194:0.005713:0.012508:0.007466:0.012508:0.013143:0.005657:0.012450:0.011738:0.005330:0.005201:0.003848:0.011738:0.005330:0.005205:0.006523:0.011738:0.003848:0.007466:0.010545:0.013143:0.005711:0.012508:0.013143:0.005330:0.005205:0.011738:0.013143:0.007466:0.010545:0.006042:0.012604:0.006388
cused on a more-specific immunotherapy :@0.084242:0.112490:0.480497:0.112490:0.480497:0.096734:0.084242:0.096734:0.012450:0.011699:0.007466:0.012508:0.013181:0.005134:0.012604:0.011738:0.005130:0.013143:0.005136:0.018049:0.012604:0.005707:0.012508:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005136:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
approach and has led to the develop-:@0.084242:0.128815:0.475136:0.128815:0.475136:0.113059:0.084242:0.113059:0.013143:0.013123:0.013123:0.005719:0.012604:0.013143:0.012450:0.011738:0.010198:0.013143:0.011738:0.013181:0.010198:0.011738:0.013143:0.007466:0.010198:0.003848:0.012508:0.013181:0.010198:0.006523:0.012604:0.010198:0.006523:0.011738:0.012508:0.010198:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.006388
ment  of the more targeted  checkpoint :@0.084242:0.145140:0.480507:0.145140:0.480507:0.129384:0.084242:0.129384:0.018049:0.012508:0.011738:0.006523:0.005330:0.005474:0.012604:0.006042:0.010814:0.006523:0.011738:0.012508:0.010814:0.018049:0.012604:0.005707:0.012508:0.010814:0.006523:0.013143:0.005807:0.012950:0.012508:0.006523:0.012508:0.013181:0.005330:0.005473:0.012450:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330
inhibitors.:@0.084242:0.161465:0.170102:0.161465:0.170102:0.145709:0.084242:0.145709:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330
Immune system activation is brought :@0.102426:0.177790:0.480501:0.177790:0.480501:0.162034:0.102426:0.162034:0.004349:0.018049:0.018049:0.011699:0.011738:0.012508:0.013470:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.013470:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.013470:0.003848:0.007466:0.013470:0.013123:0.005715:0.012604:0.011699:0.012950:0.011738:0.006523:0.005330
about by the presentation  of intracellu-:@0.084242:0.194114:0.475161:0.194114:0.475161:0.178358:0.084242:0.178358:0.013143:0.013123:0.012604:0.011699:0.006523:0.010352:0.013123:0.010314:0.010352:0.006523:0.011738:0.012508:0.010352:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005013:0.012604:0.006042:0.010352:0.003848:0.011738:0.006523:0.005792:0.013143:0.012450:0.012508:0.003848:0.003848:0.011699:0.006388
lar  peptide  fragments  on  the  surface  of :@0.084242:0.210439:0.480494:0.210439:0.480494:0.194683:0.084242:0.194683:0.003848:0.013143:0.005792:0.005330:0.003897:0.013123:0.012508:0.013123:0.006523:0.003848:0.013181:0.012508:0.005330:0.003895:0.006042:0.005792:0.013143:0.012950:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330:0.003889:0.012604:0.011738:0.005330:0.003889:0.006523:0.011738:0.012508:0.005330:0.003895:0.007466:0.011699:0.006710:0.006042:0.013143:0.012450:0.012508:0.005330:0.003895:0.012604:0.006042:0.005330
antigen-presenting  cells (APCs). These :@0.084242:0.226764:0.480486:0.226764:0.480486:0.211008:0.084242:0.211008:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.006388:0.013123:0.005709:0.012508:0.007466:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.005330:0.012382:0.012450:0.012508:0.003848:0.003848:0.007466:0.017722:0.007100:0.014239:0.011392:0.015644:0.007466:0.007100:0.005330:0.017722:0.008197:0.011738:0.012508:0.007466:0.012508:0.005330
peptide fragments  are  presented  in as-:@0.084242:0.243089:0.475167:0.243089:0.475167:0.227333:0.084242:0.227333:0.013123:0.012508:0.013123:0.006523:0.003848:0.013181:0.012508:0.010545:0.006042:0.005792:0.013143:0.012950:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330:0.005201:0.013143:0.005715:0.012508:0.005330:0.005203:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.012508:0.013181:0.005330:0.005197:0.003848:0.011738:0.010545:0.013143:0.007466:0.006388
sociation with the  mixed histocompat-:@0.084242:0.259414:0.475177:0.259414:0.475177:0.243658:0.084242:0.243658:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.014143:0.015990:0.003848:0.006523:0.011738:0.014143:0.006523:0.011738:0.012508:0.005330:0.008800:0.018049:0.003848:0.009236:0.012508:0.013181:0.014143:0.011738:0.003848:0.007466:0.006523:0.012604:0.012450:0.012604:0.018049:0.013123:0.013143:0.006523:0.006388
ibility  complex (MHC) molecules. These :@0.084242:0.275738:0.480495:0.275738:0.480495:0.259982:0.084242:0.259982:0.003848:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.007268:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.012585:0.007100:0.017684:0.013143:0.015644:0.007100:0.012585:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.007466:0.005330:0.012585:0.008197:0.011738:0.012508:0.007466:0.012508:0.005330
MHC-peptide complexes are recognised :@0.084242:0.292063:0.480478:0.292063:0.480478:0.276307:0.084242:0.276307:0.017684:0.013143:0.015644:0.006388:0.013123:0.012508:0.013123:0.006523:0.003848:0.013181:0.012508:0.008370:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.012508:0.007466:0.008370:0.013143:0.005715:0.012508:0.008370:0.005711:0.012508:0.012450:0.012604:0.012950:0.011738:0.003848:0.007466:0.012508:0.013181:0.005330
by T-cells and result in T-cell activation. :@0.084242:0.308388:0.480480:0.308388:0.480480:0.292632:0.084242:0.292632:0.013123:0.010314:0.010718:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.007466:0.010718:0.013143:0.011738:0.013181:0.010718:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.010718:0.003848:0.011738:0.010718:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.010718:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
This activation also leads to upregulation :@0.084242:0.324713:0.480482:0.324713:0.480482:0.308957:0.084242:0.308957:0.008197:0.011738:0.003848:0.007466:0.007889:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.007889:0.013143:0.003848:0.007466:0.012604:0.007889:0.003848:0.012508:0.013143:0.013181:0.007466:0.007889:0.006523:0.012604:0.007889:0.011699:0.013123:0.005715:0.012508:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
of the cytotoxic T-lymphocyte antigen 4 :@0.084242:0.341037:0.480501:0.341037:0.480501:0.325282:0.084242:0.325282:0.012604:0.006042:0.009159:0.006523:0.011738:0.012508:0.009159:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.009159:0.008197:0.006388:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.009159:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.009159:0.010660:0.005330
(CTLA-4) which functions as a physiologi-:@0.084242:0.357362:0.475133:0.357362:0.475133:0.341606:0.084242:0.341606:0.007100:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.007100:0.008063:0.015990:0.011738:0.003848:0.012450:0.011738:0.008063:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.008063:0.013143:0.007466:0.008063:0.013143:0.008063:0.013123:0.011738:0.010314:0.007466:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.006388
cal brake via an inhibitory feedback loop :@0.084242:0.373687:0.480501:0.373687:0.480501:0.357931:0.084242:0.357931:0.012450:0.013143:0.003848:0.006100:0.013123:0.005792:0.013143:0.009660:0.012508:0.006086:0.010660:0.003848:0.013143:0.006100:0.013143:0.011738:0.006086:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.010314:0.006088:0.006042:0.012508:0.012508:0.013181:0.013123:0.013143:0.012450:0.009660:0.006100:0.003848:0.012604:0.012604:0.013123:0.005330
(see Figure 1A). Ipilimumab is a monoclo-:@0.084242:0.390012:0.475152:0.390012:0.475152:0.374256:0.084242:0.374256:0.007100:0.007466:0.012508:0.012508:0.006687:0.009333:0.003848:0.012950:0.011699:0.005711:0.012508:0.006685:0.010660:0.014239:0.007100:0.005330:0.006683:0.004349:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013143:0.013123:0.006696:0.003848:0.007466:0.006685:0.013143:0.006696:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012596:0.006388
nal antibody directed against CTLA-4 (see :@0.084242:0.406337:0.480478:0.406337:0.480478:0.390581:0.084242:0.390581:0.011738:0.013143:0.003848:0.005080:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005080:0.013181:0.003848:0.005713:0.012508:0.012450:0.006523:0.012508:0.013181:0.005070:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.005080:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.005068:0.007100:0.007466:0.012508:0.012508:0.005330
Figure  1B). Phase III trials, including both :@0.084242:0.422661:0.480505:0.422661:0.480505:0.406905:0.084242:0.406905:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.005330:0.004031:0.010660:0.011045:0.007100:0.005330:0.009371:0.011392:0.011738:0.013143:0.007466:0.012508:0.009371:0.004349:0.004349:0.004349:0.009371:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005330:0.009371:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.009371:0.013123:0.012604:0.006523:0.011738:0.005330
previously treated and untreated disease, :@0.084242:0.438986:0.480486:0.438986:0.480486:0.423230:0.084242:0.423230:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005503:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.005494:0.013143:0.011738:0.013181:0.005503:0.011699:0.011738:0.006523:0.005705:0.012508:0.013143:0.006523:0.012508:0.013181:0.005492:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.005330
have shown that ipilimumab provides im-:@0.084242:0.455311:0.475152:0.455311:0.475152:0.439555:0.084242:0.439555:0.011738:0.013143:0.010660:0.012508:0.007081:0.007466:0.011738:0.012604:0.015990:0.011738:0.007081:0.006523:0.011738:0.013143:0.006523:0.007081:0.003848:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013143:0.013123:0.007100:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.012508:0.007466:0.007081:0.003848:0.018049:0.006388
proved response rates, response duration, :@0.084242:0.471636:0.480494:0.471636:0.480494:0.455880:0.084242:0.455880:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.005567:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005565:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.005561:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005569:0.013181:0.011699:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
progression-free survival and overall surviv-:@0.523643:0.096086:0.914550:0.096086:0.914550:0.080330:0.523643:0.080330:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005715:0.012508:0.012508:0.004472:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004483:0.013143:0.011738:0.013181:0.004483:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.004483:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.006388
al. Importantly,  extended  follow-up sug-:@0.523643:0.112411:0.914566:0.112411:0.914566:0.096655:0.523643:0.096655:0.013143:0.003848:0.005330:0.010314:0.004349:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.005330:0.004974:0.012508:0.009236:0.006523:0.012508:0.011738:0.013181:0.012508:0.013181:0.005330:0.004968:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.006388:0.011699:0.013123:0.010314:0.007466:0.011699:0.012950:0.006388
gests ipilimumab results in durable remis-:@0.523643:0.128736:0.914519:0.128736:0.914519:0.112980:0.523643:0.112980:0.012950:0.012508:0.007466:0.006523:0.007466:0.008659:0.003848:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013154:0.013123:0.008659:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.008659:0.003848:0.011738:0.008659:0.013181:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.008659:0.005711:0.012508:0.018049:0.003848:0.007466:0.006388
sions with long-term survival approaching :@0.523643:0.145061:0.919886:0.145061:0.919886:0.129305:0.523643:0.129305:0.007466:0.003848:0.012604:0.011738:0.007466:0.007023:0.015990:0.003848:0.006523:0.011738:0.007008:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006319:0.018049:0.007014:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007023:0.013143:0.013123:0.013123:0.005717:0.012604:0.013143:0.012450:0.011738:0.003848:0.011738:0.012950:0.005330
20% (10-year overall survival rate of 21%).:@0.523643:0.161385:0.898385:0.161385:0.898385:0.145629:0.523643:0.145629:0.010660:0.010660:0.014913:0.004522:0.007100:0.010660:0.010660:0.006388:0.010314:0.012508:0.013143:0.005792:0.004522:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.004522:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004537:0.005792:0.013143:0.006523:0.012508:0.004522:0.012604:0.006042:0.004522:0.010660:0.010660:0.014913:0.007100:0.005330
4-6:@0.898385:0.155859:0.914540:0.155859:0.914540:0.146673:0.898385:0.146673:0.006215:0.003724:0.006215
A second inhibitory pathway results via :@0.541818:0.177806:0.919852:0.177806:0.919852:0.162050:0.541818:0.162050:0.014239:0.007658:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.007658:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.010314:0.007658:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.007658:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.007658:0.010660:0.003848:0.013143:0.005330
programmed cell-death receptor 1 (PD-1). :@0.523634:0.194131:0.919875:0.194131:0.919875:0.178375:0.523634:0.178375:0.013123:0.005715:0.012604:0.012950:0.005792:0.013143:0.018049:0.018049:0.012508:0.013181:0.003866:0.012450:0.012508:0.003848:0.003848:0.006388:0.013181:0.012508:0.013143:0.006523:0.011738:0.003877:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.003864:0.010660:0.003887:0.007100:0.011392:0.014316:0.006388:0.010660:0.007100:0.005330:0.005330
This receptor is present on activated T-cells :@0.523634:0.210455:0.919873:0.210455:0.919873:0.194699:0.523634:0.194699:0.008197:0.011738:0.003848:0.007466:0.004426:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.004412:0.003848:0.007466:0.004426:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.004416:0.012604:0.011738:0.004414:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.012508:0.013181:0.004426:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
and binds to its ligand, (PD-L1). Similarly to :@0.523634:0.226780:0.919864:0.226780:0.919864:0.211024:0.523634:0.211024:0.013143:0.011738:0.013181:0.005696:0.013123:0.003848:0.011738:0.013181:0.007466:0.005707:0.006523:0.012604:0.005696:0.003848:0.006523:0.007466:0.005696:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.005330:0.005696:0.007100:0.011392:0.014316:0.006388:0.008890:0.010660:0.007100:0.005330:0.005696:0.009583:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.003848:0.010314:0.005713:0.006523:0.012604:0.005330
CTLA-4 above, this interaction serves as a :@0.523634:0.243105:0.919885:0.243105:0.919885:0.227349:0.523634:0.227349:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.006508:0.013143:0.013123:0.012604:0.010660:0.012508:0.005330:0.006514:0.006523:0.011738:0.003848:0.007466:0.006523:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011726:0.006514:0.007466:0.012508:0.005792:0.010660:0.012508:0.007466:0.006523:0.013143:0.007466:0.006523:0.013143:0.005330
physiological brake  and the  immune  re-:@0.523634:0.259430:0.914543:0.259430:0.914543:0.243674:0.523634:0.243674:0.013123:0.011738:0.010314:0.007466:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.009121:0.013123:0.005792:0.013143:0.009660:0.012508:0.005330:0.003779:0.013143:0.011738:0.013181:0.009121:0.006523:0.011738:0.012508:0.005330:0.003775:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.005330:0.003781:0.005713:0.012508:0.006388
sponse is down-modulated  (see Figure 1 :@0.523634:0.275754:0.919877:0.275754:0.919877:0.259999:0.523634:0.259999:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.008755:0.003848:0.007466:0.008755:0.013181:0.012604:0.015990:0.011738:0.006388:0.018049:0.012604:0.013181:0.011699:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.003416:0.007100:0.007466:0.012508:0.012508:0.008755:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.008755:0.010660:0.005330
C). Certain tumour cells express PD-L1 and :@0.523634:0.292079:0.919869:0.292079:0.919869:0.276323:0.523634:0.276323:0.015644:0.007100:0.005330:0.004907:0.015644:0.012508:0.005792:0.006514:0.013143:0.003848:0.011738:0.004907:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004895:0.012450:0.012508:0.003848:0.003848:0.007466:0.004907:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.004907:0.011392:0.014316:0.006388:0.008890:0.010660:0.004907:0.013143:0.011738:0.013181:0.005330
this allows for evasion of the immune sys-:@0.523634:0.308404:0.914504:0.308404:0.914504:0.292648:0.523634:0.292648:0.006523:0.011738:0.003848:0.007466:0.007293:0.013143:0.003848:0.003848:0.012604:0.015990:0.007466:0.007293:0.006042:0.012604:0.005792:0.007293:0.012508:0.010660:0.013143:0.007466:0.003848:0.012604:0.011738:0.007293:0.012604:0.006042:0.007293:0.006523:0.011738:0.012508:0.007293:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.007293:0.007466:0.010314:0.007466:0.006388
tem by the  tumour  cell. Pembrolizumab :@0.523634:0.324729:0.919887:0.324729:0.919887:0.308973:0.523634:0.308973:0.006523:0.012508:0.018049:0.010006:0.013123:0.010314:0.010006:0.006523:0.011738:0.012508:0.005330:0.004664:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.004662:0.012450:0.012508:0.003848:0.003848:0.005330:0.010006:0.011392:0.012508:0.018049:0.013123:0.005715:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
and nivolumab are monoclonal antibod-:@0.523634:0.341054:0.914549:0.341054:0.914549:0.325298:0.523634:0.325298:0.013143:0.011738:0.013181:0.007408:0.011738:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.007399:0.013143:0.005715:0.012508:0.007397:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012592:0.011738:0.013143:0.003848:0.007408:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.006388
ies directed  against  the  PD-1  receptor :@0.523634:0.357378:0.919894:0.357378:0.919894:0.341622:0.523634:0.341622:0.003848:0.012508:0.007466:0.012738:0.013181:0.003848:0.005719:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330:0.007389:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.005330:0.007399:0.006523:0.011738:0.012508:0.005330:0.007389:0.011392:0.014316:0.006388:0.010660:0.005330:0.007399:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330
and allow for immune-system activation :@0.523634:0.373703:0.919854:0.373703:0.919854:0.357947:0.523634:0.357947:0.013143:0.011738:0.013181:0.009968:0.013143:0.003848:0.003848:0.012604:0.015990:0.009968:0.006042:0.012604:0.005792:0.009968:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.009968:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
(see Figure 1D). Both agents have shown :@0.523634:0.390028:0.919883:0.390028:0.919883:0.374272:0.523634:0.374272:0.007100:0.007466:0.012508:0.012508:0.007351:0.009333:0.003848:0.012950:0.011699:0.005711:0.012508:0.007341:0.010660:0.014316:0.007100:0.005330:0.007339:0.011045:0.012604:0.006523:0.011738:0.007339:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.007339:0.011738:0.013143:0.010660:0.012508:0.007351:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330
improved response rates, progression-free :@0.523634:0.406353:0.919898:0.406353:0.919898:0.390597:0.523634:0.390597:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.006158:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.006158:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.006144:0.013123:0.005717:0.012604:0.012950:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005713:0.012508:0.012508:0.005330
survival and overall survival when  com-:@0.523634:0.422678:0.914531:0.422678:0.914531:0.406922:0.523634:0.406922:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.010949:0.013143:0.011738:0.013181:0.010949:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.010949:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.010949:0.015990:0.011738:0.012508:0.011738:0.005330:0.005607:0.012450:0.012604:0.018049:0.006388
pared with chemotherapy.  In addition, :@0.523634:0.439002:0.919894:0.439002:0.919894:0.423246:0.523634:0.423246:0.013123:0.013143:0.005717:0.012508:0.013181:0.012469:0.015990:0.003848:0.006523:0.011738:0.012469:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.007120:0.004349:0.011738:0.012469:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
they are associated with a lower risk of ad-:@0.523634:0.455327:0.914543:0.455327:0.914543:0.439571:0.523634:0.439571:0.006523:0.011738:0.012508:0.010314:0.004503:0.013143:0.005715:0.012508:0.004503:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.004503:0.015990:0.003848:0.006523:0.011738:0.004503:0.013143:0.004503:0.003848:0.012604:0.015990:0.012508:0.005792:0.004503:0.005792:0.003848:0.007466:0.009660:0.004503:0.012604:0.006042:0.004503:0.013143:0.013181:0.006388
verse events.  Importantly, data suggest :@0.523634:0.471652:0.919886:0.471710:0.919886:0.455954:0.523634:0.455896:0.010660:0.012508:0.005792:0.007466:0.012508:0.007707:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.015538:0.007707:0.004349:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.007701:0.013181:0.013143:0.006523:0.013143:0.007716:0.007466:0.011699:0.012950:0.012950:0.012508:0.007466:0.006523:-0.123217
7,8:@0.647004:0.466091:0.662541:0.466091:0.662541:0.456905:0.647004:0.456905:0.006215:0.003107:0.006215
Figure 1. New modalities of cancer treatment for NSCLC: focus on immunotherapy:@0.084233:0.502931:0.779011:0.502931:0.779011:0.486540:0.084233:0.486540:0.009756:0.005272:0.011257:0.011218:0.007158:0.010160:0.003887:0.010680:0.005003:0.003887:0.013220:0.010043:0.014605:0.003887:0.016548:0.011161:0.011468:0.010160:0.005292:0.005272:0.007062:0.005272:0.010160:0.008351:0.003887:0.011103:0.006562:0.003887:0.008753:0.010160:0.011276:0.008467:0.010160:0.007312:0.003887:0.007062:0.007158:0.010160:0.010006:0.007062:0.016548:0.010160:0.011161:0.007062:0.003887:0.006367:0.011103:0.007312:0.003887:0.013277:0.010391:0.011449:0.009102:0.011449:0.005003:0.003887:0.006369:0.011159:0.008678:0.011218:0.008351:0.003887:0.011103:0.011276:0.003887:0.005272:0.016548:0.016548:0.011218:0.011276:0.011103:0.007062:0.011276:0.010160:0.007100:0.010160:0.011334:0.010064
Activated :@0.801211:0.528786:0.884856:0.528786:0.884856:0.513905:0.801211:0.513905:0.012103:0.010582:0.005545:0.003271:0.009061:0.011171:0.005545:0.010631:0.011204:0.004531
CD8+ T-cell:@0.801211:0.543479:0.890335:0.543479:0.890335:0.528599:0.801211:0.528599:0.013297:0.012169:0.009061:0.009912:0.004531:0.006968:0.005430:0.010582:0.010631:0.003271:0.003271
Deactivated :@0.403030:0.532407:0.508543:0.532407:0.508543:0.517527:0.403030:0.517527:0.012169:0.010631:0.011171:0.010582:0.005545:0.003271:0.009061:0.011171:0.005545:0.010631:0.011204:0.004531
CD8+ T-cell:@0.403030:0.547101:0.492154:0.547101:0.492154:0.532220:0.403030:0.532220:0.013297:0.012169:0.009061:0.009912:0.004531:0.006968:0.005430:0.010582:0.010631:0.003271:0.003271
Deactivated :@0.378787:0.733786:0.484300:0.733786:0.484300:0.718906:0.378787:0.718906:0.012169:0.010631:0.011171:0.010582:0.005545:0.003271:0.009061:0.011171:0.005545:0.010631:0.011204:0.004531
CD8+ T-cell:@0.378787:0.748479:0.467912:0.748479:0.467912:0.733599:0.378787:0.733599:0.013297:0.012169:0.009061:0.009912:0.004531:0.006968:0.005430:0.010582:0.010631:0.003271:0.003271
Tumour antigen :@0.178716:0.533516:0.306439:0.533516:0.306439:0.518635:0.178716:0.518635:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.011171:0.009977:0.005545:0.003271:0.011008:0.010631:0.009977:0.004531
presentation:@0.190394:0.548209:0.290214:0.548209:0.290214:0.533328:0.190394:0.533328:0.011155:0.004856:0.010631:0.006346:0.010631:0.009977:0.005545:0.011171:0.005545:0.003271:0.010713:0.009977
Tumour antigen :@0.196292:0.743491:0.324015:0.743491:0.324015:0.728610:0.196292:0.728610:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.011171:0.009977:0.005545:0.003271:0.011008:0.010631:0.009977:0.004531
presentation:@0.207970:0.758184:0.307790:0.758184:0.307790:0.743303:0.207970:0.743303:0.011155:0.004856:0.010631:0.006346:0.010631:0.009977:0.005545:0.011171:0.005545:0.003271:0.010713:0.009977
MHC:@0.181162:0.565752:0.220661:0.565752:0.220661:0.550872:0.181162:0.550872:0.015031:0.011171:0.013297
MHC:@0.194495:0.774580:0.233995:0.774580:0.233995:0.759700:0.194495:0.759700:0.015031:0.011171:0.013297
TCR:@0.273691:0.561703:0.303884:0.561703:0.303884:0.546822:0.273691:0.546822:0.006968:0.013297:0.009928
TCR:@0.280363:0.770264:0.310556:0.770264:0.310556:0.755383:0.280363:0.755383:0.006968:0.013297:0.009928
B7:@0.286229:0.597119:0.304679:0.597119:0.304679:0.582239:0.286229:0.582239:0.009388:0.009061
CTLA-4:@0.311297:0.606000:0.365713:0.606000:0.365713:0.591119:0.311297:0.591119:0.013297:0.006968:0.007556:0.012103:0.005430:0.009061
CTLA-4: B7 binding:@0.316859:0.644541:0.463180:0.644541:0.463180:0.629661:0.316859:0.629661:0.013297:0.006968:0.007556:0.012103:0.005430:0.009061:0.004531:0.004531:0.009388:0.009061:0.004531:0.011155:0.003271:0.009977:0.011204:0.003271:0.009977:0.011008
Anti-CTLA-4 :@0.776969:0.658369:0.872243:0.658369:0.872243:0.643489:0.776969:0.643489:0.012103:0.009977:0.005545:0.003271:0.005430:0.013297:0.006968:0.007556:0.012103:0.005430:0.009061:0.004531
antibody:@0.776969:0.673063:0.848772:0.673063:0.848772:0.658182:0.776969:0.658182:0.011171:0.009977:0.005545:0.003271:0.011155:0.010713:0.011204:0.008767
CTLA-4:@0.760605:0.632536:0.815022:0.632536:0.815022:0.617655:0.760605:0.617655:0.013297:0.006968:0.007556:0.012103:0.005430:0.009061
CD28:@0.751817:0.620453:0.795406:0.620453:0.795406:0.605572:0.751817:0.605572:0.013297:0.012169:0.009061:0.009061
CD28:@0.385947:0.606000:0.429536:0.606000:0.429536:0.591119:0.385947:0.591119:0.013297:0.012169:0.009061:0.009061
B7:@0.718181:0.634619:0.736631:0.634619:0.736631:0.619739:0.718181:0.619739:0.009388:0.009061
Activated :@0.802423:0.735453:0.886068:0.735453:0.886068:0.720572:0.802423:0.720572:0.012103:0.010582:0.005545:0.003271:0.009061:0.011171:0.005545:0.010631:0.011204:0.004531
CD8+ T-cell:@0.802423:0.750146:0.891547:0.750146:0.891547:0.735265:0.802423:0.735265:0.013297:0.012169:0.009061:0.009912:0.004531:0.006968:0.005430:0.010582:0.010631:0.003271:0.003271
Cytolytic molecules:@0.595151:0.750036:0.750174:0.750036:0.750174:0.735155:0.595151:0.735155:0.013297:0.008767:0.005545:0.010713:0.003271:0.008767:0.005545:0.003271:0.010582:0.004531:0.015342:0.010713:0.003271:0.010631:0.010582:0.009944:0.003271:0.010631:0.006346
Tumour cell growth :@0.253497:0.883161:0.407616:0.883161:0.407616:0.868280:0.253497:0.868280:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.010582:0.010631:0.003271:0.003271:0.004531:0.011008:0.004854:0.010713:0.013592:0.005545:0.009977:0.004531
and proliferation:@0.253497:0.897854:0.385015:0.897854:0.385015:0.882974:0.253497:0.882974:0.011171:0.009977:0.011204:0.004531:0.011155:0.004856:0.010713:0.003271:0.003271:0.005136:0.010631:0.004923:0.011171:0.005545:0.003271:0.010713:0.009977
Tumour cell:@0.535151:0.877744:0.624519:0.877744:0.624519:0.862864:0.535151:0.862864:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.010582:0.010631:0.003271:0.003271
Tumour cell:@0.102424:0.883161:0.191792:0.883161:0.191792:0.868280:0.102424:0.868280:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.010582:0.010631:0.003271:0.003271
PD-L1:@0.671818:0.855869:0.715717:0.855869:0.715717:0.840989:0.671818:0.840989:0.009683:0.012169:0.005430:0.007556:0.009061
PD-L1:@0.272215:0.832783:0.316115:0.832783:0.316115:0.817903:0.272215:0.817903:0.009683:0.012169:0.005430:0.007556:0.009061
PD1: PD-L1:@0.346666:0.849750:0.430540:0.849750:0.430540:0.834869:0.346666:0.834869:0.009683:0.012169:0.009061:0.004531:0.004531:0.009683:0.012169:0.005430:0.007556:0.009061
binding:@0.346666:0.864443:0.406529:0.864443:0.406529:0.849562:0.346666:0.849562:0.011155:0.003271:0.009977:0.011204:0.003271:0.009977:0.011008
PD-1:@0.321212:0.821820:0.357555:0.821820:0.357555:0.806939:0.321212:0.806939:0.009683:0.012169:0.005430:0.009061
PD-L:@0.783213:0.839828:0.818051:0.839828:0.818051:0.824947:0.783213:0.824947:0.009683:0.012169:0.005430:0.007556
Anti-PD-1 antibody:@0.735151:0.864203:0.884154:0.864203:0.884154:0.849322:0.735151:0.849322:0.012103:0.009977:0.005545:0.003271:0.005430:0.009683:0.012169:0.005430:0.009061:0.004531:0.011171:0.009977:0.005545:0.003271:0.011155:0.010713:0.011204:0.008767
Source: Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Dovepress. Accessed :@0.083485:0.917801:0.915342:0.917801:0.915342:0.905547:0.083485:0.905547:0.007453:0.009803:0.009100:0.004505:0.009683:0.009728:0.004146:0.004146:0.011135:0.010222:0.008291:0.002993:0.009728:0.005807:0.004146:0.013754:0.004146:0.004146:0.011075:0.009728:0.012437:0.004146:0.014038:0.009803:0.010252:0.010222:0.002993:0.002993:0.005074:0.002993:0.009728:0.005807:0.004146:0.009803:0.004699:0.004146:0.009683:0.010222:0.009129:0.009683:0.009728:0.004505:0.004146:0.005074:0.004505:0.009728:0.010222:0.005074:0.014038:0.009728:0.009129:0.005074:0.004146:0.004699:0.009803:0.004505:0.004146:0.011075:0.007453:0.012168:0.006914:0.012168:0.004146:0.004146:0.004699:0.009803:0.009683:0.009100:0.005807:0.004146:0.009803:0.009129:0.004146:0.002993:0.014038:0.014038:0.009100:0.009129:0.009803:0.005074:0.009129:0.009728:0.004505:0.010222:0.010207:0.008022:0.004146:0.004146:0.011135:0.009803:0.008291:0.009728:0.010207:0.004505:0.009728:0.005807:0.005807:0.004146:0.004146:0.011075:0.009683:0.009683:0.009728:0.005807:0.005807:0.009728:0.010252:0.004146
January 2018. https://www.dovepress.com/new-modalities-of-cancer-treatment-for-nsclc-focus-on-immunothera-:@0.083485:0.931033:0.906767:0.931033:0.906767:0.918779:0.083485:0.918779:0.007214:0.010222:0.009129:0.009100:0.010222:0.004505:0.008022:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.004146:0.009129:0.005074:0.005074:0.010207:0.005807:0.004146:0.006540:0.006540:0.012437:0.012437:0.012437:0.004146:0.010252:0.009803:0.008291:0.009728:0.010207:0.004505:0.009728:0.005807:0.005807:0.004146:0.009683:0.009803:0.014038:0.006540:0.009129:0.009728:0.012437:0.004969:0.014038:0.009803:0.010252:0.010222:0.002993:0.002993:0.005074:0.002993:0.009728:0.005807:0.004969:0.009803:0.004699:0.004969:0.009683:0.010222:0.009129:0.009683:0.009728:0.004505:0.004969:0.005074:0.004505:0.009728:0.010222:0.005074:0.014038:0.009728:0.009129:0.005074:0.004969:0.004699:0.009803:0.004505:0.004969:0.009129:0.005807:0.009683:0.002993:0.009683:0.004969:0.004699:0.009803:0.009683:0.009100:0.005807:0.004969:0.009803:0.009129:0.004969:0.002993:0.014038:0.014038:0.009100:0.009129:0.009803:0.005074:0.009129:0.009728:0.004505:0.010177:0.004969
py-peer-reviewed-fulltext-article-CMAR.:@0.083485:0.944265:0.370658:0.944265:0.370658:0.932011:0.083485:0.932011:0.010207:0.008022:0.004969:0.010207:0.009728:0.009728:0.004505:0.004969:0.004505:0.009728:0.008291:0.002993:0.009728:0.012437:0.009728:0.010252:0.004969:0.004699:0.009100:0.002993:0.002993:0.005074:0.009728:0.007184:0.005074:0.004969:0.010222:0.004505:0.005074:0.002993:0.009683:0.002993:0.009728:0.004969:0.012168:0.013754:0.011075:0.009085:0.004146
Tumour cell death:@0.599393:0.888578:0.741820:0.888578:0.741820:0.873697:0.599393:0.873697:0.006214:0.009944:0.015342:0.010713:0.009944:0.004923:0.004531:0.010582:0.010631:0.003271:0.003271:0.004531:0.011204:0.010631:0.011171:0.005545:0.009977